Copyright
©The Author(s) 2024.
World J Gastroenterol. Feb 14, 2024; 30(6): 556-564
Published online Feb 14, 2024. doi: 10.3748/wjg.v30.i6.556
Published online Feb 14, 2024. doi: 10.3748/wjg.v30.i6.556
Table 2 Incidence of adverse effects among the study groups
Analysis | QT-10 | QT-14 | OST-14 | P value1 |
ITT | 39% | 42.7% | 24.7% | 0.03 |
PP | 45.1% | 49.5% | 31.3% | 0.01 |
- Citation: Seddik H, Benass J, Berrag S, Sair A, Berraida R, Boutallaka H. Optimized sequential therapy vs 10- and 14-d concomitant therapy for eradicating Helicobacter pylori: A randomized clinical trial. World J Gastroenterol 2024; 30(6): 556-564
- URL: https://www.wjgnet.com/1007-9327/full/v30/i6/556.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i6.556